
ANIX Stock Forecast & Price Target
ANIX Analyst Ratings
Bulls say
Anixa Biosciences Inc. is advancing its oncology-focused therapies, with positive Phase 1 data for its breast cancer vaccine, showing immune responses in 74% of participants, and encouraging survival signals from its ovarian cancer CAR-T therapy, lira-cel. The CAR-T therapy's selective targeting of the follicle-stimulating hormone receptor (FSHR) on ovarian cancer cells suggests a reduced risk of off-target toxicity, enhancing its therapeutic profile. These promising clinical advancements and strategic regulatory approvals bolster investor confidence and underscore Anixa's potential for significant impact in treating critical cancer indications.
Bears say
Anixa Biosciences has faced significant challenges, including a lack of commercialized products in its pipeline, which raises concerns regarding future revenue generation. The reliance on developing therapies and vaccines for high-incidence cancers places the company in a highly competitive market, where failure to secure timely clinical advancements may hinder its financial stability. Additionally, the presence of legacy operations with limited revenue contributions suggests ongoing financial strain, further reinforcing a cautious perspective on the company's overall growth outlook.
This aggregate rating is based on analysts' research of Anixa Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
ANIX Analyst Forecast & Price Prediction
Start investing in ANIX
Order type
Buy in
Order amount
Est. shares
0 shares